Navigation Links
Chimerix Appoints Two New Vice Presidents to Clinical Management Team
Date:7/21/2010

RESEARCH TRIANGLE PARK, N.C., July 21 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that it has expanded its clinical management team with the appointment of Timothy King, MSPH, as Vice President of Clinical Operations and Herve Mommeja-Marin, MD, as Vice President of Clinical Research.  

In these new roles, Mr. King will oversee clinical operations and site management for Chimerix and Dr. Mommeja-Marin will oversee clinical strategy and study design.  Both individuals will report to Wendy Painter, MD, Chief Medical Officer.  

"Tim King and Herve Mommeja-Marin bring to Chimerix a wealth of talent and knowledge within infectious diseases which will be of great value as we advance of our antiviral clinical development programs," said Kenneth I. Moch, President and CEO. "We anticipate significant progress in our two clinical stage programs - CMX001 against double-stranded DNA viruses and CMX157 against HIV - and look forward to working with Tim and Herve as we develop these assets."

Mr. King has over 20 years of global experience managing and directing device and drug development clinical trials.  Most recently he served as a Group Director at Quintiles, where he had responsibility for more than 20 Phase I to IV trials in over 40 countries for a wide range of drugs, biologics, devices and diagnostics. Mr. King's prior experience includes serving as the Head of Clinical Operations for Infectious Diseases, Hepatology, Vaccines, and Transplants at Duke Clinical Research Institute, where he oversaw programs in cytomegalovirus, hepatitis, and HIV.  Mr. King holds a masters degree in epidemiology from the University of North Carolina.  

Dr. Mommeja-Marin brings to Chimerix over 20 years of global medical and clinical research experience in infectious and respiratory disease and clinical medicine.  Most recently he was Senior Medical Director, Infectious Diseases, for i3 Research, a contract research organization, where he was the lead therapeutic expert in infectious diseases.  His background includes numerous Phase I through Phase IV clinical trials, including more than 25 late-stage trials. Previously, Dr. Mommeja-Marin was Director of Clinical Research for Gilead Sciences, Inc., where he was responsible for the global development of hepatitis B and hepatitis C programs. He also held the positions of Clinical Research Physician at Triangle Pharmaceuticals and Physician of Internal Medicine and Infectious Diseases at Assistance Publique- Hopitaux de Paris in France. Dr. Mommeja-Marin received a medical degree from Paris VII University, France.  He is certified in internal medicine and multiple subspecialties.

About Chimerix

Chimerix is developing antiviral therapeutics to treat life-threatening diseases.  Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, adenovirus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.  The company's lead compound, CMX001, is in Phase 1 and Phase 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients.  CMX001 is also being developed as a biodefense countermeasure in the event of a smallpox release.  Chimerix has advanced a second antiviral compound, CMX157, into Phase 1 clinical studies.  CMX157 is being developed as a potential once-weekly nucleoside analogue against HIV infections.  Building on the company's extensive chemical library, Chimerix is also pursuing translational medicine efforts to address malaria, dengue fever and other public health needs.  Chimerix has received financing from leading venture capital firms, including Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Company and Frazier Healthcare Ventures, as well as significant funding from the National Institute of Allergy and Infectious Diseases.  Additional information about Chimerix and its antiviral drug development programs may be found online at http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chimerix to Present at Upcoming Investor Conferences
2. Chimerix Initiates Phase 1 Study of CMX157
3. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
4. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
5. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
6. Chimerix Joins International Network of Organizations to Cure Malaria
7. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
8. SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents
9. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
10. Bacterin International Appoints Three New Members to Its Board of Directors
11. Shire plc Appoints Two New Board Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today ... based Phase 1 trial with severe kidney ... reducing inflamed protein biomarkers in patients with severe kidney ... this is the first time in medical history that ... between epigenetic regulation and its potential for positive disease ...
(Date:1/23/2017)... ... January 23, 2017 , ... CallTower is proud to announce ... of the Year Award winner for 2017. , For three consecutive years, CallTower ... In 2016, CallTower was awarded with the hosted VoIP Excellence award and in 2015, ...
(Date:1/21/2017)... -- Bioptix, Inc. (Nasdaq: BIOP ... 14, 2017 the Board of Directors of the Company ... certain employees associated with the September 2016 acquisition of ... on January 16, 2017 and terminations are expected to ... severance benefits in certain circumstances of up to one ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo Bioworks, ... Gen9, a pioneer in the synthesis and assembly ... expertise in assembling pathway-length synthetic DNA into Ginkgo,s ... capacity in the construction of new organism designs ... "Gen9 was founded to significantly increase ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec. 16, 2016   IdentyTechSolutions ... Identity management products and solutions and a cutting-edge ... today that it is offering seamless, integrated solutions ... security entrance products. The solutions provide IdentyTech,s customers ... secure their facilities from crime and theft. ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in mobile ... market" The mobile biometrics market is expected to grow ... billion by 2022, at a CAGR of 29.3% between ... such as the growing demand for smart devices, government ... "Software component is expected to grow at ...
Breaking Biology News(10 mins):